MRRS adds "Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach and is the fifth-most common cancer globally. There are many types of gastric cancer, but adenocarcinoma is the most common type and is diagnosed in 95% of cases. The life expectancy and survival rate for gastric cancer is heavily dependent on the stage of the disease when diagnosed. In Asia-Pacific, most of the incident cases of gastric cancer are diagnosed at the late stage and in patients over the age of 60. As the aged population continues to grow, the prevalence of gastric cancer will increase. This, coupled with increasing early diagnosis and an improved survival rate, will drive revenue growth. Due to its indolent nature, the disease remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved targeted therapeutic options. The current marketed products landscape comprises a wide range of treatment options, including HER2-targeted therapy, angiogenesis inhibitors and new chemotherapies. Nevertheless, significant unmet need remains for products that can treat HER2-negative gastric cancer patients. However, the gastric cancer market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on targeted therapies.

In the current market, patients with HER2-positive gastric cancer can be treated with targeted therapies, such as Herceptin, while HER2-negative patients still receive chemotherapy regimens as the first-line treatment. The market will be driven by recently launched products and upcoming targeted therapies during the forecast period. The main restraints will be the low penetration of new targeted therapies, owing to their high price, and constrained healthcare budgets.

Table of Contents
3 Marketed Products 21
3.1 Overview 21
3.2 HER2-Targeted Therapy 21
3.2.1 Herceptin (trastuzumab) – Roche/Genentech 21
3.3 Angiogenesis Inhibitors 23
3.3.1 Cyramza (ramucirumab) – Eli Lilly 23
3.3.2 Aitan (apatinib) – Jiangsu HengRui Medicine 24
3.4 Newer Chemotherapies 25
3.4.1 TS-1 (tegafur, gimeracil, oteracil) – Taiho 26
3.4.2 Abraxane (nab-paclitaxel) – Celgene/Taiho 26
3.5 Comparative Efficacy and Safety of Marketed Products 27
4 Pipeline Analysis 29
4.1 Overview 29
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 29
4.3 Pipeline by Molecular Target 31
4.4 Promising Pipeline Candidates 33
4.4.1 Opdivo (nivolumab) – Ono Pharmaceutical/Bristol-Myers Squibb 33
4.4.2 Keytruda (pembrolizumab) – Merck 35
4.4.3 Perjeta (pertuzumab) – Roche 37
4.4.4 Napabucasin – Boston Biomedical (subsidiary of Dainippon Sumitomo Pharma) 39
4.4.5 Lynparza (olaparib) – AstraZeneca 41
4.4.6 Nimotuzumab – Kuhnil Pharmaceutical/Daiichi Sankyo 43
4.4.7 Avelumab – Merck 44
4.4.8 GS-5745 – Gilead Bioscience 46
4.5 Comparative Efficacy and Safety of Pipeline Products 47
4.6 Product Competitive Framework 48
5 Clinical Trial Analysis 50......

List of Tables and Figures 
Table 1: Gastric Cancer, Tumor, Node and Metastasis Staging 17
Table 2: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Discovery, 2016 89
Table 3: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016 90
Table 4: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2016 92
Table 5: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2016 93
Table 6: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase II, 2016 95
Table 7: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2016 97
Table 8: Gastric Cancer Therapeutics Market, Asia-Pacific, Market Forecast, 2015–2022 97
Table 9: Gastric Cancer Therapeutics Market, India, Market Forecast, 2015–2022 98
Table 10: Gastric Cancer Therapeutics Market, China, Market Forecast, 2015–2022 98
Table 11: Gastric Cancer Therapeutics Market, Australia, Market Forecast, 2015–2022 99
Table 12: Gastric Cancer Therapeutics Market, South Korea, Market Forecast, 2015–2022 99
Table 13: Gastric Cancer Therapeutics Market, Japan, Market Forecast, 2015–2022 100.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/gastric-cancer-therapeutics-in-asia-pacific-markets-to-2022-growth-driven-by-increasing-prevalence-and-launch-of-targeted-therapies

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/